Laddar...
Pathogen Acquisition in Patients with Cystic Fibrosis Receiving Ivacaftor or Lumacaftor/Ivacaftor
BACKGROUND: The CFTR modulators ivacaftor and lumacaftor/ivacaftor improve the status of existing infections in patients with cystic fibrosis (CF). It is unknown how well these drugs protect patients against incident infections. We hypothesized that CFTR modulator treatment would decrease new infect...
Sparad:
| I publikationen: | Pediatr Pulmonol |
|---|---|
| Huvudupphovsmän: | , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6641998/ https://ncbi.nlm.nih.gov/pubmed/31012285 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ppul.24341 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|